Martin Reck, MD, PhD, on Immunotherapy for Thoracic Malignancies: Expert Perspective
ESMO 2018 CongressMartin Reck, MD, PhD, of the LungenClinic, discusses recent updates on biomarkers beyond PD-L1 expression; mechanisms and management of resistance; as well as combinations and novel approaches in lung cancer.
Related Videos
Karl Lewis, MD, on Basal Cell Carcinoma: An Ongoing Study
Karl Lewis, MD, of the University of Colorado, discusses a phase II study of cemiplimab in patients with advanced basal cell carcinoma who experienced progression of disease on, or...
Suresh S. Ramalingam, MD, on Lung Cancer: Research Highlights
Suresh S. Ramalingam, MD, of the Emory University School of Medicine, summarizes the top-line lung cancer results reported at this year’s ESMO Congress, including the role of targe...
Eileen M. O’Reilly, MD, on Hepatobiliary Cancer: Multimodality Approaches
Eileen M. O’Reilly, MD, of Memorial Sloan Kettering Cancer Center, discusses the latest information on locoregional and systemic treatments of hepatocellular carcinoma as well as t...
Laurence Albiges, MD, PhD, on RCC: Challenging Established Front-Line Treatment
Laurence Albiges, MD, PhD, of Gustave Roussy, discusses data from the global, phase III JAVELIN trial that compared axitinib plus avelumab vs sunitinib, which could lead to a new s...
Ronald de Wit, MD, PhD, on Bladder Cancer: Results From KEYNOTE-057
Ronald de Wit, MD, PhD, of the University Medical Center Rotterdam, discusses phase II findings on the efficacy of pembrolizumab in Bacillus Calmette Geurin–unresponsive bladder ca...
